Propofol enhances BCR-ABL TKIs’ inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression

BACKGROUND: The anti-cancer activities of intravenous anesthetic drug propofol have been demonstrated in various types of cancers but not in chronic myeloid leukemia (CML). METHODS: We systematically examined the effect of propofol and its combination with BCR-ABL tyrosine kinase inhibitors (TKIs) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Zhimin, Peng, Aixia, Xu, Jingwen, Ouyang, Mingwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622516/
https://www.ncbi.nlm.nih.gov/pubmed/28962554
http://dx.doi.org/10.1186/s12871-017-0423-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622516/
https://www.ncbi.nlm.nih.gov/pubmed/28962554
http://dx.doi.org/10.1186/s12871-017-0423-2

Ejemplares similares